On October 10, 2023, a joint decision was made by the U.S. federal Drug Enforcement Administration (DEA) and the U.S. Department of Health and Human Services (HHS). This decision details a newly published temporary rule. This rule has extended until December 31, 2024, the capacity for DEA-registered practitioners to prescribe controlled substances via telemedicine without any requirement of a prior in-person medical evaluation of the patient. Pullman & Comley – Connecticut Health Law reports on the matter.
This extended rule is set to have substantial effects, particularly on medical practitioners in Connecticut. DEA registered practitioners who have hitherto utilized telemedicine to make prescriptions for patients are granted further leeway by this extension.
Telemedicine can bring many benefits, such as making healthcare more accessible, particularly for patients who may find it challenging to travel for in-person consultations. However, the expanded capacity to prescribe without a direct patient consultation must be balanced against controls for the potential misuse of prescribed substances.
Professionals in the legal sector, especially those working within medical law, health law, and associated fields, will need to take this ruling into account both within their practice and in advising their clients.
The DEA and HHS’s decision again underlines the increasing importance of telemedicine within the healthcare system. It presents new challenges, opportunities, and considerations for both the legal profession and the medical establishment at large.